NATH BIOGENES (INDIA)
Back to Balance Sheet
|
NATH BIOGENES (INDIA) Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2013 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹17 Cr | ₹7.87 Cr | ₹3.19 Cr | ₹3.28 Cr | ₹1.79 Cr |
What is the latest Total Non-Current Liabilities ratio of NATH BIOGENES (INDIA) ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹17 Cr |
| Mar2024 | ₹7.87 Cr |
| Mar2023 | ₹3.19 Cr |
| Mar2022 | ₹3.28 Cr |
| Mar2013 | ₹1.79 Cr |
How is Total Non-Current Liabilities of NATH BIOGENES (INDIA) Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹17 Cr | 110.04 | |
| Mar2024 | ₹7.87 Cr | 146.55 | |
| Mar2023 | ₹3.19 Cr | -2.60 | |
| Mar2022 | ₹3.28 Cr | 82.96 | |
| Mar2013 | ₹1.79 Cr | - | |
Compare Total Non-Current Liabilities of peers of NATH BIOGENES (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATH BIOGENES (INDIA) | ₹372.4 Cr | 15.3% | 51.2% | 8.9% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹10,472.1 Cr | 0.3% | 9.1% | -20.9% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹4,960.0 Cr | 2.5% | 21.8% | -35.1% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,232.1 Cr | 4.4% | 30.5% | -7.8% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,033.1 Cr | -3.6% | 46.1% | -27.8% | Stock Analytics | |
| INDO US BIOTECH | ₹210.6 Cr | 2.5% | 4.9% | -39.3% | Stock Analytics | |
NATH BIOGENES (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATH BIOGENES (INDIA) | 15.3% |
51.2% |
8.9% |
| SENSEX | -1% |
2.2% |
-3.6% |
You may also like the below Video Courses